Mythic Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Out of Business

Mythic Therapeutics General Information

Description

Developer of a biotechnology product platform designed to deliver chemotherapy directly to tumors through antibody-drug conjugates. The company's technology increases uptake in cancerous cells while avoiding payload release in normal cells, increases efficacy for a wide range of targets and cancer types without causing unacceptable side effects or toxicity, enabling medical practitioners to realize the full potential of patients, treat a broad array of tumor targets, and leave a lasting impact on cancer care.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Beaver Street
  • Suite 303
  • Waltham, MA 02453
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 100 Beaver Street
  • Suite 303
  • Waltham, MA 02453
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mythic Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 16-Jan-2026 Completed Out of Business
6. Later Stage VC 24-Dec-2024 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 15-Dec-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 13-Aug-2020 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 01-Jan-2019 Completed Clinical Trials - Phase 1
2. Seed Round 11-Jun-2018 $4.75M $4.75M Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Mythic Therapeutics’s complete valuation and funding history, request access »

Mythic Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 9,018,393 $0.000100 $0.15 $1.89 $1.89 $1.89 22.26%
Seed 3,140,645 $0.000100 $0.12 $1.51 $1.51 $1.51 7.75%
To view Mythic Therapeutics’s complete cap table history, request access »

Mythic Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology product platform designed to deliver chemotherapy directly to tumors through antibody-drug
Drug Discovery
Waltham, MA
14 As of 2026

South San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mythic Therapeutics Competitors (5)

One of Mythic Therapeutics’s 5 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Egenesis Venture Capital-Backed Cambridge, MA
Sutro Biopharma Formerly VC-backed South San Francisco, CA
4D Molecular Therapeutics Formerly VC-backed Emeryville, CA
Personal Genome Diagnostics Formerly VC-backed Baltimore, MD
You’re viewing 5 of 5 competitors. Get the full list »

Mythic Therapeutics Patents

Mythic Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026112478-A1 Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof Pending 24-Nov-2024
WO-2026112478-A8 Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof Pending 24-Nov-2024
WO-2025245128-A1 Antibody drug conjugates and therapeutic uses thereof Pending 20-May-2024
WO-2025212647-A1 Antigen-binding protein constructs and uses thereof Pending 01-Apr-2024
WO-2024263932-A2 Itgb6-binding proteins and uses thereof Inactive 23-Jun-2023 C07K16/2842
To view Mythic Therapeutics’s complete patent history, request access »

Mythic Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mythic Therapeutics FAQs

  • When was Mythic Therapeutics founded?

    Mythic Therapeutics was founded in 2017.

  • Where is Mythic Therapeutics headquartered?

    Mythic Therapeutics is headquartered in Waltham, MA.

  • What is the size of Mythic Therapeutics?

    Mythic Therapeutics has 14 total employees.

  • What industry is Mythic Therapeutics in?

    Mythic Therapeutics’s primary industry is Drug Discovery.

  • Is Mythic Therapeutics a private or public company?

    Mythic Therapeutics is a Private company.

  • What is Mythic Therapeutics’s current revenue?

    The current revenue for Mythic Therapeutics is .

  • How much funding has Mythic Therapeutics raised over time?

    Mythic Therapeutics has raised $156M.

  • Who are Mythic Therapeutics’s competitors?

    CytomX Therapeutics, Egenesis, Sutro Biopharma, 4D Molecular Therapeutics, and Personal Genome Diagnostics are competitors of Mythic Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process